Barinthus Biotherapeutics
20400 Century Blvd
Germantown
Maryland
United States
Tel: +441865591439
Website: https://www.barinthusbio.com/careers/
Email: recruitment@barinthusbio.com
About Barinthus Biotherapeutics
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer. The company stands apart through its broad pipeline, built around four proprietary platform technologies;ChAdOx, MVA, SNAP-TI and SNAP-CI. These platforms are enabling the company to develop antigen-specific immunotherapeutics that aim to optimize the disease-fighting capabilities of T cells and guide them towards a healthy balance. Leading the way with a passion for science embodies everything we do at Barinthus Biotherapeutics – even our new name. Barinthus was the name of the mythological navigator who guided the legendary King Arthur of Britain by ship to the island of Avalon to be healed after he was wounded. Like Barinthus, our company aims to be a strong and resilient guide, navigating those that rely on us toward better health. In this most important journey, our vessel is the power of science and our expertise to harness it in directing the immune system to help people overcome chronic infectious diseases, autoimmunity, and cancer. While our eyes are keenly focused on moving science forward, we also draw inspiration from the past. Aligning the name of our company with an Arthurian legend is a nod to our rich UK-based history as a dedicated steward of science and unwavering champion of patients. If the past is prologue for the future, then we proudly embrace the values and technological approach that continue to be the hallmark and fabric of our company – now more than ever as we blaze on as Barinthus Biotherapeutics.
79 articles about Barinthus Biotherapeutics
-
Future Planet Invests in Vaccitech’s Series B Financing
3/17/2021
Future Planet Capital has invested in a $168m Series B financing announced by Vaccitech Ltd. Future Planet joins other leading investors including M&G Investment Management, Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund and fellow existing investor, Oxford Sciences Innovation.
-
Infectious disease-focused Vaccitech, which partnered with AstraZeneca and Oxford University on the development and manufacturing of that company’s COVID-19 vaccine, raised $168 million in a Series B financing round.
-
BioSpace Movers & Shakers, March 5
3/5/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
It was a busy week for clinical trial updates. Here’s a look.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
-
BioSpace Global Roundup, June 25
6/25/2020
Biopharma and life sciences companies provide updates on their pipelines and business plans. -
Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate
4/30/2020
Vaccitech Ltd and the University of Oxford announce an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University.
-
BioSpace Global Roundup, March 26
3/26/2020
Pharma and life sciences companies from across the globe provide updates on their pipelines and business practices. -
BioSpace Global Roundup, Dec. 19
12/19/2019
Companies from across the globe provide updates on their business and product pipelines. -
Vaccitech Oncology Limited enters collaboration with Cancer Research UK to fund a Phase I/IIa clinical trial as first-line NSCLC therapy
12/18/2019
Vaccitech Ltd announced that its strategic collaboration with the Ludwig Institute for Cancer Research, Vaccitech Oncology Limited, has entered into a clinical partnership with Cancer Research UK to develop VOLT’s VTP-600 immunotherapy as a treatment option for patients with non-small cell lung cancer.
-
BioSpace Global Roundup, Nov. 28
11/28/2019
Companies from across the globe provide updates on their businesses and pipelines. -
Vaccitech provides update on clinical progress for its two Phase 2 Universal Influenza studies
11/25/2019
Vaccitech progresses clinical development of Universal Influenza A Vaccine (VTP-100) in Belgium and Australia and expects top-line data in early 2020
-
BioSpace Movers & Shakers, Aug. 30
8/30/2019
Biopharma companies strengthen their leadership and boards with these appointments. -
Vaccitech Appoints Bill Enright as New Chief Executive Officer
8/27/2019
Vaccitech announced that it has appointed Bill Enright as its new Chief Executive Officer.
-
Vaccitech Appoints Chief Medical Officer to Oversee Development of Growing Clinical Pipeline of T Cell-Inducing Viral Vector Vaccines
7/15/2019
Mariem brings over 15 years’ experience in the Biopharmaceutical Industry, spent both advancing the clinical development and commercialisation of Infectious Disease products, and in delivering post-marketing monitoring of licensed medical products.
-
Vaccitech Universal flu vaccine passes Phase 2b clinical development milestones
6/5/2019
Vaccitech Ltd. announces that it has administered its pandemic universal influenza A vaccine MVA-NP+M1 (VTP-100) to the first participants in a Flu 010 study – a Phase 2b, randomised, double-blind, placebo controlled, influenza challenge study being conducted in Antwerp, Belgium.
-
The 2017/2018 influenza season was considered one of the worst, made more so by the ineffectiveness of the season’s flu vaccine. The FDA is focusing partially on simply determining why this year’s flu vaccine missed the mark.
-
The company says the vaccine takes a novel approach.
-
Vaccitech is an Oxford University spinout company developing a universal flu vaccine, among other vaccine-related products.